
Stefano Arcangeli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9039098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	1.1	2
2	Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy. Strahlentherapie Und Onkologie, 2022, 198, 448-457.	2.0	5
3	Stereotactic radiotherapy for liver oligometastases. Reports of Practical Oncology and Radiotherapy, 2022, 27, 32-39.	0.6	2
4	Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears. Lung Cancer, 2022, , .	2.0	0
5	Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy. Frontiers in Oncology, 2022, 12, 883725.	2.8	7
6	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the â€radio talk' webinars. Expert Review of Anticancer Therapy, 2022, 22, 549-559.	2.4	1
7	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2021, 147, 793-802.	2.5	0
8	The Italian Association of Radiotherapy and Oncology Recommendation for Breast Tumor Recurrence: Grades of Recommendation, Assessment, Development and Evaluation Criteria. Journal of Breast Cancer, 2021, 24, 241.	1.9	6
9	Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development) Tj ETQq1	. Þ .Q.7 843	81 4 rgBT /O
10	Oncology (AIRO). Breast, 2021, 55, 119-127. In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.6	3
11	Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis. Tumori, 2021, 107, 489-497.	1.1	3
12	Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation,) Tj ETQq0 0 0 rgl	BT /Overlo 4.4	ock 10 Tf 50
	and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 159, 103235. Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the		
13	Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Cancer Treatment Reviews, 2021, 95, 102176.	7.7	17
14	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	3.7	4
15	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	7.7	18
16	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 162, 103345.	4.4	9
17	Safety culture to improve accidental events reporting in radiotherapy. Journal of Radiological Protection, 2021, 41, .	1.1	0
18	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	7.7	30

STEFANO ARCANGELI

#	Article	IF	CITATIONS
19	Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking. Radiation Oncology, 2021, 16, 180.	2.7	7
20	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiotherapy and Oncology, 2021, 164, 104-114.	0.6	10
21	Back to (new) normality—A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108.	2.5	5
22	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	2.7	31
23	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.6	9
24	High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience. Journal of Contemporary Brachytherapy, 2020, 12, 533-539.	0.9	8
25	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	1.1	8
26	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 (Reviews in Oncology/Hematology, 2019, 134, 104-119.	Ο rgBT /Ον 4.4	verlock 10 Tf 10
27	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 C Reviews in Oncology/Hematology, 2019, 134, 87-103.).784314 r 4.4	rgBT /Over o 7
28	Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?. Cancer, 2018, 124, 3618-3619.	4.1	0
29	Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials. Cancer Treatment Reviews, 2018, 70, 22-29.	7.7	8
30	Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. Journal of Clinical Oncology, 2017, 35, 1891-1897.	1.6	141
31	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	7.7	40
32	Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?. Nature Reviews Urology, 2016, 13, 400-408.	3.8	27
33	A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective. Critical Reviews in Oncology/Hematology, 2016, 97, 322-327.	4.4	12
34	"Hit the primary― A paradigm shift in the treatment of metastatic prostate cancer?. Critical Reviews in Oncology/Hematology, 2016, 97, 231-237.	4.4	18
35	Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?. Reports of Practical Oncology and Radiotherapy, 2015, 20, 425-429.	0.6	9
36	Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Critical Reviews in Oncology/Hematology, 2015, 93, 136-148.	4.4	6

STEFANO ARCANGELI

#	Article	IF	CITATIONS
37	Toxicity of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: A Potential Comparison Bias. Journal of Clinical Oncology, 2014, 32, 3454-3454.	1.6	8
38	From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 553-564.	2.4	28
39	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology, 2013, 8, 171.	2.7	98
40	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	4.4	52
41	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	1.1	18
42	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	3.7	185
43	Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1172-1178.	0.8	187
44	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critical Reviews in Oncology/Hematology, 2012, 84, 101-108.	4.4	44
45	A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010. 78. 11-18.	0.8	243